Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Immunol Rev. 2024 Mar;322(1):178-211. doi: 10.1111/imr.13306. Epub 2024 Jan 16.
The thymus is the primary site of T-cell development, enabling generation, and selection of a diverse repertoire of T cells that recognize non-self, whilst remaining tolerant to self- antigens. Severe congenital disorders of thymic development (athymia) can be fatal if left untreated due to infections, and thymic tissue implantation is the only cure. While newborn screening for severe combined immune deficiency has allowed improved detection at birth of congenital athymia, thymic disorders acquired later in life are still underrecognized and assessing the quality of thymic function in such conditions remains a challenge. The thymus is sensitive to injury elicited from a variety of endogenous and exogenous factors, and its self-renewal capacity decreases with age. Secondary and age-related forms of thymic dysfunction may lead to an increased risk of infections, malignancy, and autoimmunity. Promising results have been obtained in preclinical models and clinical trials upon administration of soluble factors promoting thymic regeneration, but to date no therapy is approved for clinical use. In this review we provide a background on thymus development, function, and age-related involution. We discuss disease mechanisms, diagnostic, and therapeutic approaches for primary and secondary thymic defects.
胸腺是 T 细胞发育的主要场所,能够产生和选择识别非自身的多样化 T 细胞 repertoire,同时对自身抗原保持耐受。如果不进行治疗,严重的先天性胸腺发育障碍(无胸腺)会因感染而致命,而胸腺组织移植是唯一的治愈方法。虽然新生儿的严重联合免疫缺陷筛查可以在出生时更好地发现先天性无胸腺,但后天获得的胸腺疾病仍然认识不足,评估此类情况下的胸腺功能质量仍然是一个挑战。胸腺对各种内源性和外源性因素引起的损伤很敏感,其自我更新能力随年龄的增长而下降。继发性和与年龄相关的胸腺功能障碍可能会增加感染、恶性肿瘤和自身免疫的风险。在给予促进胸腺再生的可溶性因子的临床前模型和临床试验中已经取得了可喜的结果,但迄今为止,尚无批准用于临床使用的疗法。在这篇综述中,我们提供了关于胸腺发育、功能和与年龄相关的退化的背景知识。我们讨论了原发性和继发性胸腺缺陷的疾病机制、诊断和治疗方法。